Notably, GSK3β agonists wortmannin have been found to limit the positive effects of AMPK on AD, emphasizing the pivotal role of GSK3β in AMPK‐mediated suppression of p‐tau.139. The gene discussed is GSK3B; the disease is Alzheimer disease.